Analyst firms Jefferies, TD Cowen, and Raymond James Financial provided rating updates for Black Diamond Therapeutics, alongside MarketBeat consensus data.
1 report, 1 independent
Updated Oct 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst firms Jefferies, TD Cowen, and Raymond James Financial provided rating updates for Black Diamond Therapeutics, alongside MarketBeat consensus data.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Jefferies Financial Group
American financial services company
-
TD Cowen
American investment bank
Related events
- BHC received a 'hold' rating from Jefferies, while MarketBeat provided consensus data and the board initiated a stock buyback plan.
- Multiple financial firms, including Jefferies, Bank of America, and Raymond James, issued price objective and rating updates on October 23, 2026.
- Financial firms including Truist, RBC, TD Cowen, and Jefferies issued various rating updates on October 30, 2026.
- MarketBeat reported consensus rating for Hikma Pharmaceuticals, while Jefferies increased its target price and gave a buy rating. Berenberg Bank reaffirmed its buy rating, and Citigroup restated a buy rating.
- MarketBeat provided average ratings and target prices, while Jefferies Financial Group began coverage with a buy rating for Crane NXT.